Outcomes of Allogeneic Umbilical Cord Mesenchymal Stem Cell Infusion for Liver Cirrhosis Due to Biliary Atresia After Kasai Operation

jpedsurg.org

Although Kasai surgery has saved many patients with biliary atresia, the long-term survival rate remains low. Recently, cell therapy has been explored as a potential strategy to improve post-surgical survival. This study aims to evaluate the safety and outcomes of allogeneic umbilical cord mesenchymal stem cell (UC-MSC) infusion in management of liver cirrhosis due to Biliary Atresia after Kasai operation.

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · Sep 2025 · 1 min read

In brief

This study evaluates allogeneic umbilical cord mesenchymal stem cell infusion as an adjunct therapy for liver cirrhosis in biliary atresia patients post-Kasai operation. The research addresses the limited long-term survival after Kasai surgery by exploring regenerative cell-based approaches to improve hepatic outcomes in this pediatric population.

Kasai surgery for biliary atresia has limited long-term survival despite initial success in restoring bile flow.
Allogeneic umbilical cord mesenchymal stem cells (UC-MSCs) are being investigated as adjunctive therapy post-Kasai.
Cell therapy may offer a novel approach to manage progressive liver cirrhosis in biliary atresia patients.
UC-MSC infusion safety and efficacy data could inform future regenerative strategies for pediatric liver disease.

Written by the GCMD Library team from the article.

Read it at the source ↗